A new executive at a troubled company looks familiar. MiMedx Group, a tissue graft developer, announced Thursday morning that it will restate financial statements dating back to 2012 following an investigation by its audit committee into the company’s sales and distribution practices. Shares fell sharply in morning trading. MiMedx also announced that CFO Michael Senken is leaving his […]

Source: Wall Street Journal June 07, 2018 17:26 UTC